

## DAFTAR PUSTAKA

- Asano, Y. *et al.* (2016) 'Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer', *PLoS one*, 11(7), p. e0153459. doi: 10.1371/journal.pone.0153459.
- BMJ (2015) 'Primary invasive breast cancer'. Available at: <http://bestpractice.bmj.com/best-practice/monograph/716/treatment/details.html>.
- Brackstone, M. *et al.* (2015) 'Locoregional therapy of locally advanced breast cancer: A clinical practice guideline', *Current Oncology*, 22, pp. S54–S66. doi: 10.3747/co.22.2316.
- Brackstone, M. (2015) 'Response to: "Current definition of locally advanced breast cancer"', *Current Oncology*, 22(5), p. e411. doi: 10.3747/co.22.2808.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. doi: 10.3322/caac.21492.
- Cardoso, F. *et al.* (2018) '4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)', *Annals of Oncology*, 29(8), pp. 1634–1657. doi: 10.1093/annonc/mdy192.
- Christensen, S. *et al.* (2007) 'Short-term mortality after perforated or bleeding peptic ulcer among elderly patients: A population-based cohort study', *BMC Geriatrics*, 7, pp. 1–8. doi: 10.1186/1471-2318-7-8.
- Cuello-López, J. *et al.* (2018) 'Platelet-To-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer', *PLoS ONE*, 13(11), pp. 1–12. doi: 10.1371/journal.pone.0207224.
- Ghoshal, K. and Bhattacharyya, M. (2014) 'Overview of platelet physiology: Its hemostatic and nonhemostatic role in disease pathogenesis', *The Scientific World Journal*, 2014. doi: 10.1155/2014/781857.
- Herr, D. *et al.* (2019) 'Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study', *PLoS ONE*, 14(7), pp. 1–15. doi: 10.1371/journal.pone.0218434.
- Huszno, J. and Kolosza, Z. (2019) 'Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients', *Oncology Letters*, pp. 6275–6283. doi: 10.3892/ol.2019.10966.

- Kim, H. Y. *et al.* (2019) 'The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting neoadjuvant chemotherapy response in breast cancer', *Journal of Breast Cancer*, 22(3), pp. 425–438. doi: 10.4048/jbc.2019.22.e41.
- Klein, J. *et al.* (2019) 'Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: A retrospective cohort analysis', *BMC Cancer*. *BMC Cancer*, 19(1), pp. 1–11. doi: 10.1186/s12885-019-5499-2.
- Koh, C. H. *et al.* (2015) 'Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer', *British Journal of Cancer*, 113(1), pp. 150–158. doi: 10.1038/bjc.2015.183.
- Krenn-Pilko, S. *et al.* (2014) 'The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients', *British Journal of Cancer*. Nature Publishing Group, 110(10), pp. 2524–2530. doi: 10.1038/bjc.2014.163.
- LaRosa, D. F. and Orange, J. S. (2008) '1. Lymphocytes', *Journal of Allergy and Clinical Immunology*, 121(2 SUPPL. 2), pp. 364–369. doi: 10.1016/j.jaci.2007.06.016.
- Lee, J. J., Beumer, J. H. and Chu, E. (2016) 'Therapeutic drug monitoring of 5-fluorouracil', *Cancer Chemotherapy and Pharmacology*. Springer Berlin Heidelberg, 78(3), pp. 447–464. doi: 10.1007/s00280-016-3054-2.
- Lu, Y. J. *et al.* (2019) 'Prognostic values of platelet-associated indicators in advanced breast cancer', *Translational Cancer Research*, 8(4), pp. 1326–1335. doi: 10.21037/tcr.2019.07.28.
- Madondo, M. T., Quinn, M. and Plebanski, M. (2016) 'Low dose cyclophosphamide: Mechanisms of T cell modulation', *Cancer Treatment Reviews*. Elsevier Ltd, 42, pp. 3–9. doi: 10.1016/j.ctrv.2015.11.005.
- Maier, G. S. *et al.* (2015) 'Prevalence of Vitamin D deficiency in patients with bone metastases and multiple myeloma', *Anticancer Research*, 35(11), pp. 6281–6285.
- Manuaba, IBTW. (2010) 'Panduan Penatalaksanaan Kanker Payudara Peraboi', *Panduan Penatalaksanaan Kanker Solid: Sagung Seto*, pp. 17-50
- Masood, S. (2016). Neoadjuvant chemotherapy in breast cancers. *Women's Health*, 12(5), 480–491. doi:10.1177/1745505716677139
- Von Minckwitz, G. *et al.* (2008) 'Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study',

*Journal of the National Cancer Institute*, 100(8), pp. 552–562. doi: 10.1093/jnci/djn089.

- Smith, I. C. *et al.* (2002) ‘Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel’, *Journal of Clinical Oncology*, 20(6), pp. 1456–1466. doi: 10.1200/JCO.20.6.1456.
- Specht, J. and Gralow, J. R. (2009) ‘Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer’, *Seminars in Radiation Oncology*. Elsevier Inc., 19(4), pp. 222–228. doi: 10.1016/j.semradonc.2009.05.001.
- Thomas, E. *et al.* (2004) ‘The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial’, *Journal of Clinical Oncology*, 22(12), pp. 2294–2302. doi: 10.1200/JCO.2004.05.207.
- Uchida, N., Suda, T. and Ishiguro, K. (2013) ‘Effect of chemotherapy for luminal a breast cancer’, *Yonago Acta Medica*, 56(2), pp. 51–56.
- Wörmann, B. J. *et al.* (2012) ‘Breast Cancer in Women’, *Onkopedia Guidelines*. Available at: <https://www.onkopedia-guidelines.info/en/onkopedia/guidelines/breast-cancer-in-women/@@view/html/index.html#litID0EDCBG>.
- Zabotina, T. N. *et al.* (2018) ‘Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters’, *Bulletin of Experimental Biology and Medicine*, 166(2), pp. 241–244. doi: 10.1007/s10517-018-4323-3.
- Zgură, A. *et al.* (2018) ‘Relationship between tumor infiltrating lymphocytes and progression in triple negative breast cancer’, *Ginecologia.ro*, 21 (3)(1), pp. 28–30. doi: 10.26416/gine.21.3.2018.1948.
- Zhang, M. *et al.* (2017) ‘High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis’, *BioMed Research International*, 2017. doi: 10.1155/2017/9503025.
- Zhu, Y. *et al.* (2017) ‘Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer’, *Oncotarget*, 8(1), pp. 1023–1030. doi: 10.18632/oncotarget.13714.